Drug Name: | Pravastatin (81093-37-0) |
---|---|
PubChem ID: | 54687 |
SMILES: | CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O |
InchiKey: | TUZYXOIXSAXUGO-PZAWKZKUSA-N |
Therapeutic Category: | Anticholesteremic Agents, Antimetabolites, Enzyme Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Lipid Regulating Agents |
Molecular Weight (dalton) | : | 424.534 |
LogP | : | 2.4404 |
Ring Count | : | 0 |
Hydrogen Bond Acceptor Count | : | 6 |
Hydrogen Bond Donor Count | : | 4 |
Total Polar Surface Area | : | 124.29 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Atherosclerosis | Apolipoprotein E (P02649) | Progression of atherosclerosis, ischemic cardiovascular events [ ADR Type 2 ] | Faergeman O The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the |
Atherosclerosis | Liver carboxylesterase 1 (P23141) | Progression of atherosclerosis [ ADR Type 2 ] | Polymorphism of the cholesteryl ester transfer protein gene |
Bradycardia | Stromelysin-1 (P08254) | Reduction in cardiovascular events by pravastatin(death@ myocardial infarction@stroke@ angina@ and others); reduction in risk of repeated angioplasty [ ADR Type 2 ] | Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category